No data available for drug.
DRUG INTERACTION
No drug interaction found for zotepine and .
opicapone
may decrease the therapeutic effect when combined with anti-parkinson agents
rivastigmine
may decrease the therapeutic effect when combined with anti-parkinson agents
procyclidine
may decrease the therapeutic effect when combined with anti-parkinson agents
biperiden
may decrease the therapeutic effect when combined with anti-parkinson agents
benztropine
may decrease the therapeutic effect when combined with anti-parkinson agents
mibefradil
may increase the QTc-prolonging effect of each other when combined
ibandronate
may increase the QTc-prolonging effect of each other when combined
trazodone
may increase the QTc-prolonging effect of each other when combined
isradipine
may increase the QTc-prolonging effect of each other when combined
treprostinil
may increase the QTc-prolonging effect of each other when combined
bromopride
may have an increased adverse effect when combined with antipsychotic agents
bromopride
may have an increasingly adverse effect when combined with antipsychotic agents
methamphetamine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
mibefradil
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
indoramin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
terazosin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
atenolol
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
mibefradil
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
indoramin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
terazosin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
atenolol
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
levalbuterol
may enhance the hypotensive effect of beta-blockers
acebutolol
may enhance the hypotensive effect of beta-blockers
penbutolol
may enhance the hypotensive effect of beta-blockers
pindolol
may enhance the hypotensive effect of beta-blockers
propranolol
may enhance the hypotensive effect of beta-blockers
acebutolol
may increase the effect of beta-blockers
penbutolol
may increase the effect of beta-blockers
pindolol
may increase the effect of beta-blockers
famprofazone
may increase the adverse effect of amphetamines
opicapone
may reduce the therapeutic effect of antiparkinson drugs
rivastigmine
may reduce the therapeutic effect of antiparkinson drugs
procyclidine
may reduce the therapeutic effect of antiparkinson drugs
biperiden
may reduce the therapeutic effect of antiparkinson drugs
benztropine
may reduce the therapeutic effect of antiparkinson drugs
chasteberry
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
levalbuterol
may have an increased hypotensive effect when combined with beta-blockers
acebutolol
may have an increased hypotensive effect when combined with beta-blockers
betaxolol
may have an increased hypotensive effect when combined with beta-blockers
bisoprolol
may have an increased hypotensive effect when combined with beta-blockers
carvedilol
may have an increased hypotensive effect when combined with beta-blockers
dexamethasone
It may enhance the metabolism when combined with dexamethasone
famprofazone
may increase the risk of adverse effect of amphetamines
donepezil (Rx)
may have an increased neurotoxic effect when combined with antipsychotic agents
prabotulinumtoxinA
may have an increased neurotoxic effect when combined with antipsychotic agents
efonidipine
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
ropivacaine
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
halothane
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
fimasartan
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
indoramin
blood pressure lowering agents increase the effect of hypotension of antipsychotic agents
zotepine
may increase the hypotensive effect when combined with Antipsychotic Agents
cariprazine
may increase the hypotensive effect when combined with Antipsychotic Agents
chlorprothixene
may increase the hypotensive effect when combined with Antipsychotic Agents
lorpiprazole
may increase the hypotensive effect when combined with Antipsychotic Agents
lumateperone
may increase the hypotensive effect when combined with Antipsychotic Agents
tranylcypromine
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
selegiline
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
rivastigmine
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
physostigmine
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
edrophonium
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
fosinopril
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
fosnetupitant
acetylcholinesterase Inhibitors may enhance the neurotoxic (central) effect of antipsychotic Agents
methamphetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
methamphetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
rufinamide
may enhance the adverse/toxic effect of antipsychotic agents
mephenytoin
may enhance the adverse/toxic effect of antipsychotic agents
pentobarbital
may enhance the adverse/toxic effect of antipsychotic agents
perampanel
may enhance the adverse/toxic effect of antipsychotic agents
phenytoin
may enhance the adverse/toxic effect of antipsychotic agents
almasilate
antacids may reduce the absorption of antipsychotic agents
magaldrate
antacids may reduce the absorption of antipsychotic agents
levalbuterol
may increase the hypotensive effect of beta-blockers
acebutolol
may increase the hypotensive effect of beta-blockers
penbutolol
may increase the hypotensive effect of beta-blockers
pindolol
may increase the hypotensive effect of beta-blockers
propranolol
may increase the hypotensive effect of beta-blockers
rufinamide
may enhance the risk of adverse/toxic effect of antipsychotic agents
mephenytoin
may enhance the risk of adverse/toxic effect of antipsychotic agents
pentobarbital
may enhance the risk of adverse/toxic effect of antipsychotic agents
perampanel
may enhance the risk of adverse/toxic effect of antipsychotic agents
phenytoin
may enhance the risk of adverse/toxic effect of antipsychotic agents
mibefradil
may enhance the effect of antipsychotic agents
indoramin
may enhance the effect of antipsychotic agents
terazosin
may enhance the effect of antipsychotic agents
atenolol
may enhance the effect of antipsychotic agents
mibefradil
may enhance the effect of antipsychotic agents
indoramin
may enhance the effect of antipsychotic agents
terazosin
may enhance the effect of antipsychotic agents
atenolol
may enhance the effect of antipsychotic agents
diazepam
may enhance the adverse effect of antipsychotic agents
cannabidiol
may enhance the adverse/toxic effect of antipsychotic agents
carbamazepine
may enhance the adverse/toxic effect of antipsychotic agents
cenobamate
may enhance the adverse/toxic effect of antipsychotic agents
clobazam
may enhance the adverse/toxic effect of antipsychotic agents
rivastigmine
may diminish the therapeutic effect of antipsychotic agents
procyclidine
may diminish the therapeutic effect of antipsychotic agents
biperiden
may diminish the therapeutic effect of antipsychotic agents
benztropine
may diminish the therapeutic effect of antipsychotic agents
levodopa
may diminish the therapeutic effect of antipsychotic agents
stiripentol
may enhance the adverse effect of antipsychotic agents
donepezil (Rx)
may have an increased neurotoxic effect when combined with antipsychotic agents
prabotulinumtoxinA
may have an increased neurotoxic effect when combined with antipsychotic agents
cabergoline
may decrease the therapeutic effect when combined with antipsychotic agents
tetrabenazine
may have an increased adverse effect when combined with antipsychotic agents
desflurane
may increase the arrhythmogenic effect of Inhalational Anaesthetics
carbaryl
may increase the neurotoxic effect
carbaryl
may increase the neurotoxic effect
amphetamine
may have an increasingly adverse effect when combined with amphetamines
zonisamide
may increase the risk of adverse effects
ezogabine
may increase the risk of adverse effects
mexiletine
may increase the risk of adverse effects
tiagabine
may increase the risk of adverse effect
topiramate
may increase the risk of adverse effect
amifostine
may enhance the hypotensive effect of Blood Pressure Lowering Agents
deutetrabenazine
may have an increasingly adverse effect when combined with antipsychotic agent
metyrosine
metyrosine: they may increase the toxic effect of antipsychotic agents
donepezil (Rx)
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
prabotulinumtoxinA
Acetylcholinesterase Inhibitors: they may increase the neurotoxic effect of antipsychotics
moexipril
may increase the QTc-prolonging effect
alfuzosin
may increase the QTc-prolonging effect
lithium
Could potentially amplify the neurotoxicity of antipsychotic agents
zotepine
may increase the hypotensive effect when combined with Antipsychotic Agents
cariprazine
may increase the hypotensive effect when combined with Antipsychotic Agents
chlorprothixene
may increase the hypotensive effect when combined with Antipsychotic Agents
lorpiprazole
may increase the hypotensive effect when combined with Antipsychotic Agents
lumateperone
may increase the hypotensive effect when combined with Antipsychotic Agents
treprostinil
may enhance the effects of the other by pharmacodynamic synergism
mequitazine
The potential for arrhythmogenic effects of mequitazine could be intensified by the presence of antipsychotic agents
No data available for drug.
DRUG INTERACTION
zotepine
&
No Drug Intearction Found. for zotepine and .
opicapone
may decrease the therapeutic effect when combined with anti-parkinson agents
rivastigmine
may decrease the therapeutic effect when combined with anti-parkinson agents
procyclidine
may decrease the therapeutic effect when combined with anti-parkinson agents
biperiden
may decrease the therapeutic effect when combined with anti-parkinson agents
benztropine
may decrease the therapeutic effect when combined with anti-parkinson agents
mibefradil
may increase the QTc-prolonging effect of each other when combined
ibandronate
may increase the QTc-prolonging effect of each other when combined
trazodone
may increase the QTc-prolonging effect of each other when combined
isradipine
may increase the QTc-prolonging effect of each other when combined
treprostinil
may increase the QTc-prolonging effect of each other when combined
bromopride
may have an increased adverse effect when combined with antipsychotic agents
bromopride
may have an increasingly adverse effect when combined with antipsychotic agents
methamphetamine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
metamfetamine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
phentermine
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
mibefradil
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
indoramin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
terazosin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
atenolol
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
mibefradil
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
indoramin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
terazosin
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
atenolol
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
levalbuterol
may enhance the hypotensive effect of beta-blockers
acebutolol
may enhance the hypotensive effect of beta-blockers
penbutolol
may enhance the hypotensive effect of beta-blockers
pindolol
may enhance the hypotensive effect of beta-blockers
propranolol
may enhance the hypotensive effect of beta-blockers
acebutolol
may increase the effect of beta-blockers
penbutolol
may increase the effect of beta-blockers
pindolol
may increase the effect of beta-blockers
famprofazone
may increase the adverse effect of amphetamines
opicapone
may reduce the therapeutic effect of antiparkinson drugs
rivastigmine
may reduce the therapeutic effect of antiparkinson drugs
procyclidine
may reduce the therapeutic effect of antiparkinson drugs
biperiden
may reduce the therapeutic effect of antiparkinson drugs
benztropine
may reduce the therapeutic effect of antiparkinson drugs
chasteberry
It may diminish the effects when combined with chasteberry by pharmacodynamic antagonism
levalbuterol
may have an increased hypotensive effect when combined with beta-blockers
acebutolol
may have an increased hypotensive effect when combined with beta-blockers
betaxolol
may have an increased hypotensive effect when combined with beta-blockers